Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has a beta value of 1.61 and has seen 912,735 shares traded in the last trading session. The company, currently valued at $303.54 Million, closed the last trade at $10.38 per share which meant it gained $0.25 on the day or 2.47% during that session. The EIGR stock price is -52.41% off its 52-week high price of $15.82 and 56.17% above the 52-week low of $4.55. If we look at the company’s 10-day average daily trading volume, we find that it stood at 567.42 Million shares traded. The 3-month trading volume is 508.1 Million shares.

The consensus among analysts is that Eiger BioPharmaceuticals, Inc. (EIGR) is a Buy stock at the moment, with a recommendation rating of 1. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. None out of 6 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.59.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) trade information

Sporting 2.47% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Oct 16 when the EIGR stock price touched $10.56- or saw a rise of 1.7%. Year-to-date, Eiger BioPharmaceuticals, Inc. shares have moved -30.34%, while the 5-day performance has seen it change 27.52%. Over the past 30 days, the shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) have changed 3.08%. Short interest in the company has seen 1.38 Million shares shorted with days to cover at 0.

Wall Street analysts have a consensus price target for the stock at $34.17, which means that the shares’ value could jump 229.19% from current levels. The projected low price target is $23 while the price target rests at a high of $55. In that case, then, we find that the current price level is +429.87% off the targeted high while a plunge would see the stock lose 121.58% from current levels.

Eiger BioPharmaceuticals, Inc. (EIGR) estimates and forecasts

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +17% over the past 5 years. Earnings growth for 2020 is a modest +19.3%.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)’s Major holders

Insiders own 1.7% of the company shares, while shares held by institutions stand at 85.05% with a share float percentage of 86.52%. Investors are also buoyed by the number of investors in a company, with Eiger BioPharmaceuticals, Inc. having a total of 138 institutions that hold shares in the company. The top two institutional holders are 683 Capital Management LLC with over 2.16 Million shares worth more than $20.71 Million. As of June 29, 2020, 683 Capital Management LLC held 7.38% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 1.97 Million shares as of June 29, 2020. The firm’s total holdings are worth over $18.89 Million and represent 6.73% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of June 29, 2020, the former fund manager holds about 2.66% shares in the company for having 778377 shares of worth $7.47 Million while later fund manager owns 520.12 Thousand shares of worth $5.81 Million as of August 30, 2020, which makes it owner of about 1.78% of company’s outstanding stock.